Integrated Synthesis and Testing of Substituted Xanthine Based DPP4 Inhibitors: Application to Drug Discovery
- Werngard Czechtizky
- Jurgen Dedio
- Bimbisar Desai
- Karen Dixon
- Elizabeth Farrant
- Qixing Feng Trevor Morgen
- David M Parry
- Manoj K. Ramjee
- Christopher N. Selway
- Thorsten Schmidt
- Gary J. Tarver
- Adrian G. Wright
- Sanofi-Aventis, Frankfurt, Germany. Cyclofluidic Ltd., U.K.Read the publication that featured this abstract
A novel integrated discovery platform has been used to synthesize and biologically assay a series of xanthine-derived dipeptidyl peptidase 4 (DPP4) antagonists. Design, synthesis, purification, quantitation, dilution, and bioassay have all been fully integrated to allow continuous automated operation. The system has been validated against a set of known DPP4 inhibitors and shown to give excellent correlation between traditional medicinal chemistry generated biological data and platform data. Each iterative loop of synthesis through biological assay took two hours in total, demonstrating rapid iterative structure–activity relationship generation.
The Vapourtec R-Series is, quite simply, unrivalled for flow chemistry
The R-Series is undoubtedly the most versatile, modular flow chemistry system available today.
The Vapourtec E-Series is the perfect introductory system for flow chemistry
- Robust :
- Easy to use :
The E-Series is a robust and affordable, entry level flow chemistry system designed for reliability and ease of use.